Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1303507 | 0.91 | CHRM2 (0.57) | CHRM3 | |
| SCHEMBL1304099 | 0.83 | CHRM2 (0.60) | CHRM3 | |
| SCHEMBL643140 | 0.81 | CHRM3 (0.59) | CHRM3 | |
| SCHEMBL355991 | 0.80 | CHRM3 (0.67) | CHRM3 | |
| SCHEMBL356694 | 0.79 | CHRM3 (0.63) | CHRM3 | |
| SCHEMBL644587 | 0.79 | CHRM3 (0.58) | CHRM3 | |
| SCHEMBL644726 | 0.79 | CHRM3 (0.58) | CHRM3 | |
| SCHEMBL266337 | 0.79 | CHRM3 (0.60) | CHRM3 | |
| SCHEMBL645741 | 0.78 | CHRM3 (0.67) | CHRM3 | |
| SCHEMBL13590238 | 0.78 | CHRM3 (0.87) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-03-25 | — | — | US | disclosed |
| US-20220306579-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-29 | — | — | US | disclosed |
| US-11247969-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200290966-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-17 | — | — | US | disclosed |
| US-10570092-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-10343995-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190047957-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-14 | — | — | US | disclosed |
| US-10106503-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180179161-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-06-28 | — | — | US | disclosed |
| US-9926272-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-20090018165-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-01-15 | — | — | US | disclosed |
| EP-1930323-A1 | Biphenyl compounds useful in the synthesis of muscarinic receptor antagonists | Theravance, Inc. (US) | 2008-06-11 | — | — | EP | disclosed |
| EP-1723114-B1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20080095708-A1 | Biphenyl-2-ylcarbamic acid or biphenyl-2-yluurea derivatives for treatment of respiratory system disorders; chronic obstructive pulmonary disease, asthma; antihistamines, bronchodilator agents; side effect reduction | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-04-24 | — | — | US | disclosed |
| US-20080071088-A1 | Drugs for respiratory system disorders; also chemical intermediate for such drugs | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-03-20 | — | — | US | disclosed |
| US-20070292357-A1 | Use as bronchodilators for treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-([4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino)ethyl)piperidin-4-yl ester | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070292356-A1 | Bronchodilators for treating chronic obstructive pulmonary disease or asthma; long duration of action; e.g. biphenyl-2-ylcarbamic acid 1-(2-([4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino)ethylpiperidin-4-yl ester; dosage forms such as metered dose inhalers | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070265305-A1 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; biphenyl carbamate derivative | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-11-15 | — | — | US | disclosed |
| US-7288657-B2 | Biphenyl-2-ylcarbamic acid or biphenyl-2-yluurea derivatives for treatment of respiratory system disorders; chronic obstructive pulmonary disease, asthma; antihistamines, bronchodilator agents; side effect reduction | THERAVANCE, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265305-A1 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; biphenyl carbamate derivative | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-20070292357-A1 | Use as bronchodilators for treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-([4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino)ethyl)piperidin-4-yl ester | CHRM1, CHRM2, CHRM3 | CHRM3 3/4885 |
| US-20080095708-A1 | Biphenyl-2-ylcarbamic acid or biphenyl-2-yluurea derivatives for treatment of respiratory system disorders; chronic obstructive pulmonary disease, asthma; antihistamines, bronchodilator agents; side effect reduction | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-11247969-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-20220306579-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-20190047957-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-10343995-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-20070292356-A1 | Bronchodilators for treating chronic obstructive pulmonary disease or asthma; long duration of action; e.g. biphenyl-2-ylcarbamic acid 1-(2-([4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino)ethylpiperidin-4-yl ester; dosage forms such as metered dose inhalers | CHRM1, CHRM2, CHRM5 | CHRM3 4/4885 |
| US-10570092-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-20080071088-A1 | Drugs for respiratory system disorders; also chemical intermediate for such drugs | CHRM1, CHRM2, CHRM3 | CHRM3 3/4885 |
| US-10106503-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-20200290966-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-20090018165-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
| US-20180179161-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.